Dare Bioscience, Inc.

The momentum for this stock is not very good. Dare Bioscience, Inc. is not very popular among insiders. Dare Bioscience, Inc. is a mediocre stock to choose.

Daré Bioscience, Inc. operates as a healthcare company. It engages in the development and commercial...

News

Dare Bioscience announces publication in The Journal of Sexual Medicine

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Dar Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Globe Newswire Published data show that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences. Use of...\n more…

Maxim gets more bearish on Dare Bioscience, downgrades shares

Dare Bioscience announces additional data for Phase 2b RESPOND study

Dare Bioscience target adjusted to $12 from $6 at H.C. Wainwright

Dar Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Globe Newswire Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method...\n more…